Johnson & Johnson (NYSE:JNJ) reported encouraging Phase 1 data for Erda-iDRS, an investigational drug-releasing system for certain non muscle invasive bladder cancers with FGFR alterations. The study ...

This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround ...

On March 2, BofA Securities boosted its price target for Johnson & Johnson (NYSE:JNJ) to $253 from $227, while keeping a ...

Intuitive Surgical (ISRG) remains the robotic-assisted surgery market leader, with Q4 procedures up 18% and revenue rising 19% to $2.87 billion.

Johnson & Johnson (NYSE:JNJ) announced on March 5 that the U.S. Food and Drug Administration (FDA) granted approval for ...

Dividend stocks are not all the same. Some will readily decrease or suspend their payouts at the first sign of trouble, while others will continue increasing them even during mark ...

FDA approves Johnson & Johnson's Tecvayli with Darzalex Faspro for multiple myeloma after strong Phase 3 survival results.

"As golf season collides with allergy season, ZYRTEC is proud to partner with the PGA TOUR to offer relief to the 85% of ...

Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...

Of all the retirement activities you can engage in, worrying about your financial security shouldn’t be one of them. Owning dividend-paying stocks can help you relax and enjoy a more comfortable life ...

Johnson & Johnson (JNJ), Chevron (CVX), Realty Income (O), Broadcom (AVGO), and Agree Realty (ADC) for income investors.

Johnson & Johnson is a Dividend King. Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years. Its total return over the past decade tops 200%.